Judy W M Cheng

Summary

Affiliation: Massachusetts College of Pharmacy and Health Sciences
Country: USA

Publications

  1. ncbi request reprint Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure
    Patricia A Howard
    Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS 66160 7231, USA
    Ann Pharmacother 40:1607-17. 2006
  2. pmc Azilsartan/chlorthalidone combination therapy for blood pressure control
    Judy Wm Cheng
    Massachusetts College of Pharmacy and Health Sciences, Brigham and Women s Hospital, Boston, MA, USA
    Integr Blood Press Control 6:39-48. 2013
  3. doi request reprint Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115 5896, USA
    Clin Ther 34:766-87. 2012
  4. pmc A cardiovascular pharmacotherapy elective course to enhance pharmacy students' literature evaluation skills and ability to apply clinical evidence
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA
    Am J Pharm Educ 76:137. 2012
  5. doi request reprint Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Brigham and Women s Hospital, Boston, MA 02115 5896, USA
    Clin Ther 34:1209-20. 2012
  6. ncbi request reprint Key articles and guidelines in the management of arrhythmias, 2004-2010
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115 5896, USA
    Pharmacotherapy 31:1e-32e. 2011
  7. doi request reprint New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Health Syst Pharm 67:S26-34. 2010
  8. doi request reprint A review of heart failure management in the elderly population
    Judy W M Cheng
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts 02115, USA
    Am J Geriatr Pharmacother 7:233-49. 2009
  9. doi request reprint Nebivolol: a third-generation beta-blocker for hypertension
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts 02115, USA
    Clin Ther 31:447-62. 2009
  10. doi request reprint Omega-3 fatty acid: a role in the management of cardiac arrhythmias?
    Judy W M Cheng
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA
    J Altern Complement Med 14:965-74. 2008

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure
    Patricia A Howard
    Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS 66160 7231, USA
    Ann Pharmacother 40:1607-17. 2006
    ....
  2. pmc Azilsartan/chlorthalidone combination therapy for blood pressure control
    Judy Wm Cheng
    Massachusetts College of Pharmacy and Health Sciences, Brigham and Women s Hospital, Boston, MA, USA
    Integr Blood Press Control 6:39-48. 2013
    ..Edarbyclor(®) is a combined angiotensin receptor blocker (ARB) and thiazide-like diuretic (azilsartan and chlorthalidone), and was approved on December 20, 2011 by the US Food and Drug Administration (FDA) for hypertension management...
  3. doi request reprint Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115 5896, USA
    Clin Ther 34:766-87. 2012
    ....
  4. pmc A cardiovascular pharmacotherapy elective course to enhance pharmacy students' literature evaluation skills and ability to apply clinical evidence
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA
    Am J Pharm Educ 76:137. 2012
    ..To design and implement a cardiovascular pharmacotherapy elective course to enhance pharmacy students' ability to evaluate medical literature and apply clinical evidence...
  5. doi request reprint Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Brigham and Women s Hospital, Boston, MA 02115 5896, USA
    Clin Ther 34:1209-20. 2012
    ..Ticagrelor is the most recently developed P2Y(12) receptor antagonist available in the United States. Ticagrelor is a nonthienopyridine antiplatelet agent and is the first reversible oral antagonist of the P2Y(12) receptors...
  6. ncbi request reprint Key articles and guidelines in the management of arrhythmias, 2004-2010
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115 5896, USA
    Pharmacotherapy 31:1e-32e. 2011
    ..This list is an update to a previous list published in Pharmacotherapy in 2004. This article should be useful not only to practitioners and trainees in cardiovascular pharmacotherapy, but to other clinicians as well...
  7. doi request reprint New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Health Syst Pharm 67:S26-34. 2010
    ..To compare and contrast the pharmacology, efficacy, and safety of new, emerging, and established antiarrhythmic and anticoagulant medications and describe nonpharmacologic interventions for the treatment of atrial fibrillation (AF)...
  8. doi request reprint A review of heart failure management in the elderly population
    Judy W M Cheng
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts 02115, USA
    Am J Geriatr Pharmacother 7:233-49. 2009
    ..Many clinical features and the management of HF differ in elderly patients compared with their younger counterparts due to changes in physiology and the presence of comorbidities...
  9. doi request reprint Nebivolol: a third-generation beta-blocker for hypertension
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts 02115, USA
    Clin Ther 31:447-62. 2009
    ..Nebivolol is a third-generation beta(1)-selective beta-blocker that is approved for the treatment of hypertension...
  10. doi request reprint Omega-3 fatty acid: a role in the management of cardiac arrhythmias?
    Judy W M Cheng
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA
    J Altern Complement Med 14:965-74. 2008
    ..Postulated mechanisms of the antiarrhythmic effects of omega-3 fatty acid are discussed...
  11. ncbi request reprint Ambrisentan for the management of pulmonary arterial hypertension
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Ther 30:825-33. 2008
    ....
  12. doi request reprint Aliskiren: renin inhibitor for hypertension management
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Ther 30:31-47. 2008
    ..Certain agents that modify the RAAS can control blood pressure and improve cardiovascular outcomes. Aliskiren is the first of a new class of antihypertensive agents known as renin inhibitors...
  13. doi request reprint Vernakalant in the management of atrial fibrillation
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Pharmacother 42:533-42. 2008
    ..To review the pharmacology and clinical evidence of the use of vernakalant in the management of atrial fibrillation (AF)...
  14. doi request reprint Azilsartan medoxomil: a new Angiotensin receptor blocker
    Kathy Zaiken
    Massachusetts College of Pharmacy and Health Sciences and Harvard Vanguard Medical Associates, Boston, MA, USA
    Clin Ther 33:1577-89. 2011
    ..Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug Administration (FDA) for hypertension management...
  15. doi request reprint A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications
    Kathy Zaiken
    Massachusetts College of Pharmacy and Health Sciences, MCPHS University, Boston, MA, USA
    Ann Pharmacother 47:686-93. 2013
    ..To review the role of angiotensin receptor blockers (ARBs) for the prevention of cardiovascular events in patients with essential hypertension without other compelling indications...
  16. doi request reprint Pharmacoeconomic review of medical management of persistent asthma
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
    Allergy Asthma Proc 29:109-22. 2008
    ..Future economic analysis should focus on finding better ways to evaluate productivity lost due to asthma, in addition to hospitalization...
  17. doi request reprint Oral terbutaline in replacement for intravenous dopamine in a patient with end-stage heart failure
    Adele Miles
    Massaschusetts College of Pharmacy and Health Science, Boston, MA, USA
    Ann Pharmacother 47:e21. 2013
    ..To describe the replacement of intravenous dopamine with oral terbutaline in a patient with American College of Cardiology/American Heart Association stage D heart failure (HF)...
  18. doi request reprint Use of digoxin for heart failure and atrial fibrillation in elderly patients
    Judy W M Cheng
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
    Am J Geriatr Pharmacother 8:419-27. 2010
    ..Both of these are high-prevalence diseases in the elderly, and yet studies have indicated that digoxin may not be used appropriately in this population. Clinical trials evaluating digoxin use specifically in the elderly are scarce...
  19. pmc Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City
    Larisa Chagan
    Division of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA
    BMC Complement Altern Med 5:4. 2005
    ..This survey also assessed the perceptions of users regarding the safety/efficacy of BBT, types of BBT used and potential BBT-drug interactions...
  20. ncbi request reprint Rosuvastatin in the management of hyperlipidemia
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, USA
    Clin Ther 26:1368-87. 2004
    ....
  21. ncbi request reprint Key articles and guidelines in pharmacotherapeutic management of arrhythmias
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, New York, USA
    Pharmacotherapy 24:248-79. 2004
    ..This list should be useful not only to practitioners and trainees in cardiovascular pharmacotherapy, but also to other clinicians as an update...
  22. ncbi request reprint Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor
    LilyAnn Jeu
    Pharmacy Services, Veterans Affairs Medical Center, Bronx, New York, USA
    Clin Ther 25:2352-87. 2003
    ....
  23. ncbi request reprint Use of alternative pharmacotherapy in management of cardiovascular diseases
    Larisa Chagan
    Shore Health System, Easton, MD, USA
    Am J Manag Care 8:270-85; quiz 286-8. 2002
    ..To review use of alternative pharmacotherapy (AP) in patients with cardiovascular disease (CVD) and significant drug interactions between AP and traditional CVD medications...